Akzo Nobel N.v.

Akzo N.v.

Rijksuniversiteit Te Groningen

Explore Incorporated

Akco Nobel

Pieter De Haan

Ryoichi Morita

Jocominus Antonius Maria Zwinkels

Adrianus Cornelis Petrus Rovers

Theodora Antonia Maria Lambregts Vd Hurk

Coenraad F Lerk

Johannes S Van Der Hoeven

Mathias J Schaeken

Cornelus J Maria Van Der Ven

Henrika Gerardina Maria Poels-Janssen

Cornelus J Van Der Ven

M Deurloo

Carolus Paulus Thys

Marcus Johannes Deurloo

Johannes Gerardus Egberink

Jocominus Antonius Zwinkels

A stabilized pharmaceutical dosage unit comprising tibolone, in an amount of from 0.1% to 10% by weight of the dosage unit, and a pharmaceutically acceptable carrier. The dosage unit is contained in a humid atmosphere of 50 to 70% relative humidity until administration.

Stabilized tibolone compositions

The invention pertains to a pharmaceutical dosage unit, such as a tablet or a capsule, comprising an effective amount of tibolone (generally of from 0.1 to 10% by weight) and a starch-containing pharmaceutically acceptable carrier (also denoted as basic granulate), wherein the carrier contains of from 10 to 100% by weight of the starch. Thus a more stable tibolone formulation is obtained, allowing dry storage and lower doses of active ingredient.

The invention concerns a solid pharmaceutical composition comprising less than 7% by weight of an oil or oily substance, a low dosage active ingredient, and a water insoluble non-cross-linked polymeric excipient capable of binding water and having a mean particle size greater than 150 &mgr;m. The composition can be obtained by a simple procedure comprising mixing the water insoluble non-cross-linked polymeric excipient capable of binding water and the active ingredient, which is dissolved or dispersed in an oil or an oily substance, in an aqueous dispersion thereof, or in water.

Solid pharmaceutical composition comprising an excipient capable of binding water

Compressed dry-granulation desogestrel tablets

Process of making dosage units by wet granulation

The invention relates to a tablet, capsule, or granule for oral administration comprising desogestrel wherein desogestrel is mixed or dissolved in a solid selected from a lubricant free from organic solvents, and a waxy substance not being a lubricant.

Tablet capsule or granule comprising desogestrel

The invention relates to sugar-coated dosage units comprising a steroid having two hydrogen atoms at position 3 of the steroid skeleton, such as desogestrel, allylestrenol, ethylestrenol, or lynestrenol, to a process for the manufacture of such dosage units, and a use of sugar-coated compositions for providing stable dosage units comprising said steroid.

Sugar-coated pharmaceutical dosage unit

Disclosed are stabilized dry chemical (e.g. pharmaceutical) compositions containing the water soluble acid addition salt of a poorly soluble basic compound (e.g. mianserin, apomorphine, chlorpromazine, imipramine, or promethazine); an excipient selected from the group consisting of microcrystalline cellulose, lactose, calcium hydrogen phosphate, and mixtures thereof; and a water soluble (&gt;2 mg/ml) alkaline stabilizer. The resulting dry composition are relatively more bioavailable and stable than compositions not containing the water soluble alkaline stabilizer, especially after high temperature (&gt;45.degree.) granulation processes. The process for preparing the dry composition is also more 'rugged' with the added water soluble alkaline stabilizer.

Stabilized solid pharmaceutical composition containing acid addition

Disclosed are dry pharmaceutical preparations containing potent steroidal medicinal agents in combination with an excipient capable of binding the agent to an extent greater than 80% and a having a demixing potential of less than 10% for said agent. Such excipients include spray-dried polyalcohols, granulated .alpha.-lactose monohydrate, or mixtures thereof. Also disclosed is a process of manufacturing stable tablets containing nearly identical amounts of at least one steroidal medicinal agent present in each tablet in an amount varying from 0.005 to 0.5 percent by weight of the tablet. Also disclosed is a dry mix consisting essentially of 1 to 100 parts, by weight, of at least one medicinal agent uniformly distributed throughout 2000 to 20,000 parts, by weight, of the described excipients. The mixture can be used to make dry dosage forms such as capsules, tablets, powders, and slugged granulates.

Low steroid dose dry pharmaceutical preparation

Disclosed are stabilized dry chemical (e.g. pharmaceutical) compositions containing the water soluble acid addition salt of a poorly soluble basic compound (e.g. mianserin, apomorphine, chlorpromazine, imipramine, or promethazine); an excipient selected from the group consisting of microcrystalline cellulose, lactose, calcium hydrogen phosphate, and mixtures thereof; and a water soluble (&gt;2 mg/ml) alkaline stabilizer. The resulting dry compositions are relatively more bioavailable and stable than compositions not containing the water soluble alkaline stabilizer, especially after high temperature (&gt;45.degree.) granulation processes. The process for preparing the dry composition is also more 'rugged' with the added water soluble alkaline stabilizer.

The invention relates to an antimicrobial composition on the basis of a physiologically acceptable varnish dissolved therein an antimicrobial agent, preferably chlorhexidine, in an amount sufficient for elimination of Streptococcus mutans in one treatment. This composition can be applied on the tooth surface and other surfaces, such as the skin or on medical instruments.

Growing community of inventors

Oss, Netherlands

Pieter De Haan